Toll Free: 1-888-928-9744
Published: Oct, 2018 | Pages:
170 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, according to a new report by Grand View Research, Inc., progressing at a CAGR of 7.3% during the forecast period. Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market. Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo's sales, while Revlimid's patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immunotherapeutic is expected to trail behind the latter by 2027. Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner. Further key findings from the report suggest: • North America dominated the global arena in 2017, with approximately 65.0% share. The region is likely to maintain its position through 2027 • In terms of revenue, the lung cancer segment is estimated to expand at a CAGR of over 9.0% during the forecast period • The multiple myeloma segment held more than 30.0% of the market revenue in 2017 and is anticipated to lose its position to lung cancer by 2027 • Europe is projected to experience modest growth during the forecast period due to delays in cost-effectiveness analysis, carried out by health technology assessment bodies, slowing approval process and lowering reimbursement • Some of the key companies present in the market are Tesaro, Inc.; Merck &Co.; Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.
Table of Contents Chapter 1 Methodology And Scope 1.1 Research Methodology 1.2 Research Scope And Assumptions 1.3 List Of Abbreviations Chapter 2 Executive Summary 2.1 Market Summary Chapter 3 Market Variables, Trends & Scope 3.1 Market Segmentation Chapter 4 Market Definitions Chapter 5 Industry Outlook 5.1 Business Segment Trend Analysis 5.2 Pricing Analysis 5.3 Market Variable Analysis 5.3.1 Market Drivers Analysis 5.3.1.1 Accelerated Approvals Expedite Market Launch 5.3.1.2 Immuno-Oncology Therapies As First Line Treatment 5.3.2 Market Restraints Analysis 5.3.2.1 High Therapy Costs Hinders Market Access 5.4 Business Environment Analysis Tools 5.4.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological) 5.4.2 Porter's Five Forces Analysis Chapter 6 Competitive & Vendor Lanscape 6.1 Market Participation Categorization 6.1.1 Market Leaders 6.1.2 Innovators 6.2 Strategic Initiatives & Outcome Analysis 6.2.1 List Of Key Strategies, By Company 6.4 List Of Key Companies, By Region 6.5 List Of Key Companies, By Indication 6.6 List Of Key Companies, By Brands 6.7 Company Market Share Analysis Chapter 7 Regulatory And Political Forces 7.1 Regulatory Landscape 7.1.1 North America 7.1.2 Europe 7.1.3 Asia Pacific 7.1.4 Middle East & Africa 7.1.5 Latin America Chapter 8 Brands Business Analysis 8.1 Blockbuster Oncology Brands Market: Brand Analysis 8.1.1. Tagrisso 8.1.1.1 Tagrisso, By Revenue, 2015 - 2027 (USD Million) 8.1.2 Tecentriq 8.1.2.1 Tecentriq, By Revenue, 2015 - 2027 (USD Million) 8.1.3 Ibrance 8.1.3.1 Ibrance, By Revenue, 2015 - 2027 (USD Million) 8.1.4 Perjeta 8.1.4.1 Perjeta, By Revenue, 2015 - 2027 (USD Million) 8.1.5 Zejula 8.1.5.1 Zejula, By Revenue, 2015 - 2027 (USD Million) 8.1.6 Gazyva 8.1.6.1 Gazyva, By Revenue, 2015 - 2027 (USD Million) 8.1.7 Revlimid 8.1.7.1 Revlimid, By Revenue, 2015 - 2027 (USD Million) 8.1.8 Darzalex 8.1.8.1 Darzalex, By Revenue, 2015 - 2027 (USD Million) 8.1.9 Imbruvica 8.1.9.1 Imbruvica, By Revenue, 2015 - 2027 (USD Million) 8.1.10 Opdivo 8.1.10.1 Opdivo, By Revenue, 2015 - 2027 (USD Million) 8.1.11 Keytruda 8.1.11.1 Keytruda, By Revenue, 2015 - 2027 (USD Million) Chapter 9 Indications Business Analysis 9.1. Blockbuster Oncolgoy Brands: Indications Movement Analysis 9.1.1. Lung Cancer 9.1.1.1 Lung Cancer Estimates And Forecasts, 2015 - 2027 (USD Million) 9.1.2 Breast Cancer 9.1.2.1 Breast Cancer Estimates And Forecasts, 2015 - 2027 (USD Million) 9.1.3 Multiple Myeloma 9.1.3.1 Multiple Myeloma Estimates And Forecasts, 2015 - 2027 (USD Million) 9.1.4 Lymphoma 9.1.4.1 Lymphoma Estimates And Forecasts, 2015 - 2027 (USD Million) 9.1.5 Others 9.1.5.1 Lymphoma Estimates And Forecasts, 2015 - 2027 (USD Million) Chapter 10 Regional Business Analysis 10.1. Blockbuster Oncology Brands Market: Regional Movement Analysis 10.1.1. North America 10.1.1.1 North America Market Estimates And Forecast, 2015 - 2027 10.1.1.2 U.S. 10.1.1.2.1 U.S. Blockbuster Oncology Brands Market, 2015 - 2027 (USD Million) 10.1.1.3 Canada 10.1.1.3.1 Canada Blockbuster Oncology Brands Market, 2015 - 2027 (USD Million) 10.1.2. Europe 10.1.2.1 Europe Market Estimates And Forecast, 2015 - 2027 10.1.2.2 Germany 10.1.2.2.1 Germany Market Estimates And Forecast, 2015 - 2027 10.1.2.3 U.K. 10.1.2.3.1 U.K. Market Estimates And Forecast, 2015 - 2027 10.1.2.4 France 10.1.2.4.1 France Market Estimates And Forecast, 2015 - 2027 10.1.2.5 Italy 10.1.2.5.1 Italy Market Estimates And Forecast, 2015 - 2027 10.1.2.6 Spain 10.1.2.6.1 Spain Market Estimates And Forecast, 2015 - 2027 10.1.2.7 Denmark 10.1.2.7.1 Denmark Market Estimates And Forecast, 2015 - 2027 10.1.2.8 Switzerland 10.1.2.8.1 Switzerland Market Estimates And Forecast, 2015 - 2027 10.1.2.9 Poland 10.1.2.9.1 Poland Market Estimates And Forecast, 2015 - 2027 10.1.3 Asia Pacific 10.1.3.1 Asia Pacific Market Estimates And Forecast, 2015 - 2027 10.1.3.2 Japan 10.1.3.2.1 Japan Market Estimates And Forecast, 2015 - 2027 10.1.3.3 China. 10.1.3.3.1 China Market Estimates And Forecast, 2015 - 2027 10.1.3.4 India 10.1.3.4.1 India Market Estimates And Forecast, 2015 - 2027 10.1.3.5 New Zealand 10.1.3.5.1 New Zealand Market Estimates And Forecast, 2015 - 2027 10.1.3.6 Australia 10.1.3.6.1 Australia Market Estimates And Forecast, 2015 - 2027 10.1.3.7 Philippines 10.1.3.7.1 Philippines Market Estimates And Forecast, 2015 - 2027 10.1.3.8 S.Korea 10.1.3.8.1 S.Korea Market Estimates And Forecast, 2015 - 2027 10.1.3.9 Indonesia 10.1.3.9.1 Indonesia Market Estimates And Forecast, 2015 - 2027 10.1.3.10 Hong Kong 10.1.3.10.1 Hong Kong Market Estimates And Forecast, 2015 - 2027 10.1.3.11 Singapore 10.1.3.11.1 Singapore Market Estimates And Forecast, 2015 - 2027 10.1.4 Latin America 10.1.4.1 Latin America Market Estimates And Forecast, 2015 - 2027 10.1.4.2 Brazil 10.1.4.2.1 Brazil Market Estimates And Forecast, 2015 - 2027 10.1.4.3 Mexico 10.1.4.3.1 Mexico Market Estimates And Forecast, 2015 - 2027 10.1.4.4 Argentina 10.1.4.4.1 Argentina Market Estimates And Forecast, 2015 - 2027 10.1.5 Middle-East 10.1.5.1 Middle-East And Africa Market Estimates And Forecast, 2015 - 2027 10.1.5.2 Saudi Arabia 10.1.5.2.1 Saudi Arabia Market Estimates And Forecast, 2015 - 2027 10.1.5.3 Turkey. 10.1.5.3.1 Turkey Market Estimates And Forecast, 2015 - 2027 10.1.5.4 Israel 10.1.5.4.1 Israel Market Estimates And Forecast, 2015 - 2027 Chapter 11 Company Profile 11.1 BRISTOL MYERS SQUIBB 11.1.1 Company overview 11.1.2 Financial performance 11.1.3 Product overview 11.1.4 Regulatory developments 11.1.5 Product pipeline 11.1.6 Business strategies 11.1.7 Swot analysis 11.2 MERCK & CO. 11.2.1 Company overview 11.2.2 Financial performance 11.2.3 Product overview 11.2.4 Regulatory developments 11.2.5 Product pipeline 11.2.6 Business strategies 11.2.7 Swot analysis 11.3 ROCHE 11.3.1 Company overview 11.3.2 Financial performance 11.3.3 Product overview 11.3.4 Product pipeline 11.3.5 Business strategies 11.3.6 Swot analysis 11.4 PFIZER 11.4.1 Company overview 11.4.2 Financial performance 11.4.3 Product overview 11.4.4 Product pipeline 11.4.5 Business strategies 11.4.6 Swot analysis 11.5 ASTRAZENECA 11.5.1 Company overview 11.5.2 Financial performance 11.5.3 Product overview 11.5.4 Product pipeline 11.5.5 Business strategies 11.5.6 swot analysis 11.6 TESARO 11.6.1 Company overview 11.6.2 Financial performance 11.6.3 Product overview 11.6.4 Product pipeline 11.6.5 Business strategies 11.6.6 Swot analysis Chapter 12 Pipeline Analysis 12.1 Therapies in focus 12.2 Strong future players 12.3 Market outlook
List of Tables TABLE 1 Global Blockbuster Oncology Brands Market, by region, 2015 - 2027 (USD Million) TABLE 2 Global Blockbuster Oncology Brands Market, by Indications, 2015 - 2027 (USD Million) TABLE 3 Global Blockbuster Oncology Brands Market, by Brands, 2015 - 2027 (USD Million) TABLE 4 North America Market, by country, 2015 - 2027 (USD Million) TABLE 5 North America Market, by Indication, 2015 - 2027 (USD Million) TABLE 6 North America Market, by Brand, 2015 - 2027 (USD Million) TABLE 7 U.S. Market, by Indication, 2015 - 2027 (USD Million) TABLE 8 U.S. Market, by Brand, 2015 - 2027 (USD Million) TABLE 9 Canada Market, by Indication, 2015 - 2027 (USD Million) TABLE 10 Canada Market, by Brand, 2015 - 2027 (USD Million) TABLE 11 Europe Market, by country, 2015 - 2027 (USD Million) TABLE 12 Europe Market, by Indication, 2015 - 2027 (USD Million) TABLE 13 Europe Market, by Brands, 2015 - 2027 (USD Million) TABLE 14 France Market, by Brands, 2015 - 2027 (USD Million) TABLE 15 France Market, by Indication, 2015 - 2027 (USD Million) TABLE 16 Germany Market, by Indication, 2015 - 2027 (USD Million) TABLE 17 Germany Market, by Brands, 2015 - 2027 (USD Million) TABLE 18 Italy Market, by Indication, 2015 - 2027 (USD Million) TABLE 19 Italy Market, by Brands, 2015 - 2027 (USD Million) TABLE 20 Spain Market, by Indication, 2015 - 2027 (USD Million) TABLE 21 Spain Market, by Brands, 2015 - 2027 (USD Million) TABLE 22 UK Market, by Indication, 2015 - 2027 (USD Million) TABLE 23 UK Market, by Brands, 2015 - 2027 (USD Million) TABLE 24 Switzerland Market, by Indication, 2015 - 2027 (USD Million) TABLE 25 Switzerland Market, by Brands, 2015 - 2027 (USD Million) TABLE 26 Denmark Market, by Indication, 2015 - 2027 (USD Million) TABLE 27 Denmark Market, by Brands, 2015 - 2027 (USD Million) TABLE 28 Poland Market, by Indication, 2015 - 2027 (USD Million) TABLE 29 Poland Market, by Brands, 2015 - 2027 (USD Million) TABLE 30 APAC Market, by country, 2015 - 2027 (USD Million) TABLE 31 APAC Market, by Indication, 2015 - 2027 (USD Million) TABLE 32 APAC Market, by Brands, 2015 - 2027 (USD Million) TABLE 33 Hong Kong Market, by Indication, 2015 - 2027 (USD Million) TABLE 34 Hong Kong Market, by Brand, 2015 - 2027 (USD Million) TABLE 35 Singapore Market, by Indication, 2015 - 2027 (USD Million) TABLE 36 Singapore Market, by Brands, 2015 - 2027 (USD Million) TABLE 37 China Market, by Indication, 2015 - 2027 (USD Million) TABLE 38 China Market, by Brands, 2015 - 2027 (USD Million) TABLE 39 India Market, by Indication, 2015 - 2027 (USD Million) TABLE 40 India Market, by Brands, 2015 - 2027 (USD Million) TABLE 41 Japan Market, by Indication, 2015 - 2027 (USD Million) TABLE 42 Japan Market, by Brands, 2015 - 2027 (USD Million) TABLE 43 Indonesia Market, by Indication, 2015 - 2027 (USD Million) TABLE 44 Indonesia Market, by Brands, 2015 - 2027 (USD Million) TABLE 45 New Zealand Market, by Indication, 2015 - 2027 (USD Million) TABLE 46 New Zealand Market, by Brands, 2015 - 2027 (USD Million) TABLE 47 Australia Market, by Indication, 2015 - 2027 (USD Million) TABLE 48 Australia Market, by Brands, 2015 - 2027 (USD Million) TABLE 49 Philippines Market, by Indication, 2015 - 2027 (USD Million) TABLE 50 Philippines Market, by Brands, 2015 - 2027 (USD Million) TABLE 51 South Korea Market, by Indication, 2015 - 2027 (USD Million) TABLE 52 South Korea Market, by Brands, 2015 - 2027 (USD Million)) TABLE 53 Latin America Market, by country, 2015 - 2027 (USD Million) TABLE 54 Latin America Market, by Indication, 2015 - 2027 (USD Million) TABLE 55 Latin America Market, by Brands, 2015 - 2027 (USD Million) TABLE 56 Argentina Market, by Brands, 2015 - 2027 (USD Million) TABLE 57 Argentina Market, by Indication, 2015 - 2027 (USD Million) TABLE 58 Brazil Market, by Indication, 2015 - 2027 (USD Million) TABLE 59 Brazil Market, by Brands, 2015 - 2027 (USD Million) TABLE 60 Mexico Market, by Indication, 2015 - 2027 (USD Million) TABLE 61 Mexico Market, by Brands, 2015 - 2027 (USD Million) TABLE 62 MEA Market, by country, 2015 - 2027 (USD Million) TABLE 63 MEA Market, by Indication, 2015 - 2027 (USD Million) TABLE 64 MEA Market, by Brands, 2015 - 2027 (USD Million) TABLE 65 Saudi Arabia Market, by Indication, 2015 - 2027 (USD Million) TABLE 66 Saudi Arabia Market, by Brands, 2015 - 2027 (USD Million) TABLE 67 Turkey Market, by Indication, 2015 - 2027 (USD Million) TABLE 68 Turkey Market, by Brands, 2015 - 2027 (USD Million) TABLE 69 Israel Market, by Brands, 2015 - 2027 (USD Million) TABLE 70 Israel Market, by Brands, 2015 - 2027 (USD Million)
List of Figures FIG. 1 Blockbuster oncology brands market snapshot FIG. 2 Blockbuster Oncology brands market segmentation FIG. 3 Blockbuster oncology brands market driver impact FIG. 4 Blockbuster oncology brands market restraintr impact FIG. 5 SWOT Analysis, By Factor (Political & legal Economic and technological) FIG. 6 Porter's Five Forces Analysis FIG. 7 Value Chain Analysis FIG. 8 Blockbuster oncology brands market:brands outlook and key takeaways FIG. 9 Blockbuster oncology brands Market: Brands Movement Analysis FIG. 10 Tagrisso, 2015 - 2027 (USD Million) FIG. 11 Tecentriq, 2015 - 2027 (USD Million) FIG. 12 Tecentriq, 2015 - 2027 (USD Million) FIG. 13 Tecentriq, 2015 - 2027 (USD Million) FIG. 14 Zejula, 2015 - 2027 (USD Million) FIG. 15 Gazyva, 2015 - 2027 (USD Million) FIG. 16 Revlimid, 2015 - 2027 (USD Million) FIG. 17 Darzalex, 2015 - 2027 (USD Million) FIG. 18 Imbruvica, 2015 - 2027 (USD Million) FIG. 19 Opdivo, 2015 - 2027 (USD Million) FIG. 20 Keytruda, 2015 - 2027 (USD Million) FIG. 21 Blockbuster oncology brands market indication outlook and key takeaways FIG. 22 Blockbuster oncology brands Market: Indication Movement Analysis FIG. 23 Lung cancer , 2015 - 2027 (USD Million) FIG. 24 Breast cancer market, 2015 - 2027 (USD Million) FIG. 25 Multiple myeloma market, 2015 - 2027 (USD Million) FIG. 26 lymphoma market, 2015 - 2027 (USD Million) FIG. 27 Blockbuster oncology brandsmarket: regional outlook and key takeaways FIG. 28 CTMS Market: Regional Movement Analysis FIG. 29 North America FIG. 30 North America market estimates and forecast, 2015 - 2027 FIG. 31 U.S. Blockbuster Oncology Brands market, 2015 - 2027 (USD Million) FIG. 32 Canada Blockbuster Oncology Brands market, 2015 - 2027 (USD Million) FIG. 33 Europe FIG. 34 Europe market estimates and forecast, 2015 - 2027 FIG. 35 Germany market estimates and forecast, 2015 - 2027 FIG. 36 U.K. market estimates and forecast, 2015 - 2027 FIG. 37 France market estimates and forecast, 2015 - 2027 FIG. 38 Italy market estimates and forecast, 2015 - 2027 FIG. 39 Spain market estimates and forecast, 2015 - 2027 FIG. 40 Denmark market estimates and forecast, 2015 - 2027 FIG. 41 Switzerland market estimates and forecast, 2015 - 2027 FIG. 42 Poland. market estimates and forecast, 2015 - 2027 FIG. 43 Asia-Pacific FIG. 44 Asia-Pacific market estimates and forecast, 2015 - 2027 FIG. 45 Japan market estimates and forecast, 2015 - 2027 FIG. 46 China. market estimates and forecast, 2015 - 2027 FIG. 47 India market estimates and forecast, 2015 - 2027 FIG. 48 Thailand market estimates and forecast, 2015 - 2027 FIG. 49 Australia market estimates and forecast, 2015 - 2027 FIG. 50 Philippines market estimates and forecast, 2015 - 2027 FIG. 51 South Korea market estimates and forecast, 2015 - 2027 FIG. 52 Indonesia. market estimates and forecast, 2015 - 2027 FIG. 53 Hong Kong market estimates and forecast, 2015 - 2027 FIG. 54 Singapore. market estimates and forecast, 2015 - 2027 FIG. 55 Latin America FIG. 56 Latin America market estimates and forecast, 2015 - 2027 FIG. 57 Brazil market estimates and forecast, 2015 - 2027 FIG. 58 Mexico market estimates and forecast, 2015 - 2027 FIG. 59 Argentina market estimates and forecast, 2015 - 2027 FIG. 60 Middle East & Africa FIG. 61 Middle east market estimates and forecast, 2015 - 2027 FIG. 62 Suadi Arabia market estimates and forecast, 2015 - 2027 FIG. 63 Turkey market estimates and forecast, 2015 - 2027 FIG. 64 Israel market estimates and forecast, 2015 - 2027 FIG. 65 Company Profile
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.